Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -241,598 | -176,937 | -22,634 | 4,179 | 42 |
| Depreciation Amortization | 113 | 49 | 9 | N/A | N/A |
| Accounts payable and accrued liabilities | -12,948 | 5,070 | 4,809 | 5 | 59 |
| Other Working Capital | -32,674 | 5,866 | 10,373 | 228 | -416 |
| Other Operating Activity | 128,543 | 24,734 | 18,108 | -4,550 | -185 |
| Operating Cash Flow | $-158,564 | $-141,218 | $10,665 | $-138 | $-500 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -62,176 | N/A | N/A | N/A | N/A |
| PPE Investments | -672 | -24 | -221 | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 0 | -138,000 |
| Investing Cash Flow | $-62,848 | $-24 | $-221 | $N/A | $-138,000 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -83 |
| Common Stock Issued | 661,036 | 8,912 | 396,952 | N/A | 143,010 |
| Other Financing Activity | -1,529 | 0 | -5,047 | 0 | -3,062 |
| Financing Cash Flow | $659,507 | $8,912 | $391,905 | $N/A | $139,865 |
| Exchange Rate Effect | -6,802 | 5,052 | 5,248 | N/A | N/A |
| Beginning Cash Position | 340,450 | 467,728 | 60,131 | 1,365 | N/A |
| End Cash Position | 771,743 | 340,450 | 467,728 | 1,227 | 1,365 |
| Net Cash Flow | $431,293 | $-127,278 | $407,597 | $-138 | $1,365 |
| Free Cash Flow | |||||
| Operating Cash Flow | -158,564 | -141,218 | 10,665 | -138 | -500 |
| Capital Expenditure | -672 | -24 | -221 | N/A | N/A |
| Free Cash Flow | -159,236 | -141,242 | 10,444 | -138 | -500 |